Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Business Alliance on the New Radiopharmaceutical 'Metastron Injectable' (Japan)

This article was originally published in PharmAsia News

Executive Summary

Nippon Kayaku Co. is partnering with Nihon Medi-Physics. The two companies are teaming up to focus on the Japanese distribution of Metastron Injectable. A radiopharmaceutical developed by GE Healthcare, the Metastron Injectable is designed to treat pain associated with metastasized bone cancer. Under the terms of their partnership, Nippon will focus on how to best market Metastron Injectable to healthcare facilities. Nihon will then concentrate finding best practices for the injection's import and distribution as well as educating medical practitioners on its safe and effective use. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts